Colorectal Cancer Metastatic Clinical Trials

54 recruitingLast updated: June 17, 2026

There are 54 actively recruiting colorectal cancer metastatic clinical trials across 15 countries. Studies span Phase 2, Phase 1, Early Phase 1, Not Applicable, Phase 3. Top locations include Guangzhou, Guangdong, China, Hangzhou, Zhejiang, China, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Colorectal Cancer Metastatic Trials at a Glance

54 actively recruiting trials for colorectal cancer metastatic are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 30 trials, with the heaviest enrollment activity in Guangzhou, Hangzhou, and Shanghai. Lead sponsors running colorectal cancer metastatic studies include Sun Yat-sen University, Fudan University, and National Cancer Institute, Naples.

Browse colorectal cancer metastatic trials by phase

Treatments under study

About Colorectal Cancer Metastatic Clinical Trials

Looking for clinical trials for Colorectal Cancer Metastatic? There are currently 54 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colorectal Cancer Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colorectal Cancer Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 54 trials

Recruiting

China Metastatic Liver Cancer Clinical Registry Cohort Database

Liver CancerLiver MetastasesNeoplasms+3 more
Anhui Provincial Hospital2,000 enrolled3 locationsNCT07602504
Recruiting
Phase 2

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Colorectal, CancerLiver MetastasesColorectal Cancer Metastatic
Weill Medical College of Cornell University24 enrolled1 locationNCT06300463
Recruiting
Phase 2

Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)

Peritoneal CarcinomatosisColorectal Cancer MetastaticAppendiceal Neoplasms
Ciusss de L'Est de l'Île de Montréal25 enrolled1 locationNCT05913674
Recruiting
Phase 1

In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

Colorectal, CancerColorectal Cancer MetastaticLung Metastases
University Health Network, Toronto10 enrolled1 locationNCT05611034
Recruiting
Phase 2

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Colorectal Cancer MetastaticAdvanced Colorectal Cancer
Suzhou Teligene Ltd.80 enrolled1 locationNCT06589830
Recruiting
Phase 2

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

Colorectal Cancer Metastatic
Buzzard Pharmaceuticals20 enrolled2 locationsNCT06634875
Recruiting
Phase 1Phase 2

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Colorectal, CancerAdvanced Colorectal CarcinomaAdvanced Colorectal Adenocarcinoma+2 more
University of Chicago53 enrolled1 locationNCT05200442
Recruiting
Early Phase 1

INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases

Colorectal Cancer Metastatic
Northwell Health10 enrolled1 locationNCT07172282
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer

Colorectal Cancer MetastaticAdenocarcinoma of Colon
Beijing Biotech48 enrolled1 locationNCT07462650
Recruiting
Early Phase 1

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

Colorectal Cancer Metastatic
Northwell Health10 enrolled2 locationsNCT07193862
Recruiting

Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection

Colorectal Cancer MetastaticLiver Transplant SurgeryColon Cancer Liver Metastases
Northwestern University80 enrolled1 locationNCT06698146
Recruiting
Phase 2

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

Colorectal Cancer MetastaticIntrahepatic Cholangiocarcinoma
Michael J Cavnar, MD80 enrolled1 locationNCT07201519
Recruiting
Phase 1Phase 2

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

Colorectal Cancer Metastatic
Carina Biotech Limited45 enrolled1 locationNCT05759728
Recruiting
Early Phase 1

COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

Colorectal Cancer MetastaticColorectal Cancer Stage IIIColorectal Cancer Stage IV
Biogenea Pharmaceuticals Ltd.12 enrolled1 locationNCT07328087
Recruiting
Phase 2

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

Colorectal Cancer Metastatic
National Cancer Institute, Naples60 enrolled1 locationNCT07213570
Recruiting
Phase 2

ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

Colorectal Cancer Metastatic
National Cancer Institute, Naples130 enrolled8 locationsNCT06714357
Recruiting
Phase 2

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Colorectal Cancer Metastatic
Second Affiliated Hospital, School of Medicine, Zhejiang University100 enrolled1 locationNCT06540326
Recruiting
Phase 2

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

Triple Negative Breast Cancer MetastaticMelanoma MetastaticColorectal Cancer Metastatic
Fudan University95 enrolled1 locationNCT06889610
Recruiting
Phase 1Phase 2

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

ImmunotherapyColorectal Cancer MetastaticColorectal Cancer (CRC)+1 more
Anbogen Therapeutics, Inc.66 enrolled15 locationsNCT07244705
Recruiting

Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)

Colorectal Cancer MetastaticMicrosatellite Instability-High Colorectal Cancer
Federation Francophone de Cancerologie Digestive600 enrolled20 locationsNCT06353854